Non-small Cell Lung Cancer (NSCLC)
Conditions
Keywords
Non-small Cell Lung Cancer (NSCLC)
Brief summary
The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting
Interventions
DRUGApproved Non-small Cell Lung Cancer (NSCLC) therapies
As prescribed by treating physician
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients * Aged ≥18 years at the time of enrollment in the study * Resident of the US, Germany, or Japan * Able to read, speak, and understand English, German or Japanese * Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC) Physicians * Resident of the US, Germany, or Japan * Lung cancer-treating physician specialized in one of the following medical areas: oncology, pneumonology, thoracic surgery, or radiology * Treated at least three new patients with resectable NSCLC in the past year
Exclusion criteria
Patients * Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment) * Being diagnosed with another malignancy alongside NSCLC * Not willing to be audio-recorded during the interview Physicians * Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment) * Not willing to be audio-recorded during the interview
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Responses to qualitative interview questions | Day 1 | Interview questions designed to gather insights into diagnosis, symptoms, current treatments, perspectives on treatment features and test for mock preferences tasks. The interview will take 15 minutes to complete. |
| Patient sociodemographic | Day 1 | — |
| Patient clinical characteristics | Day 1 | — |
Countries
United Kingdom
Contacts
STUDY_DIRECTORBristol-Myers Squibb
Bristol-Myers Squibb
Outcome results
None listed